GSK’s Anemia Drug Jesduvroq gets US FDA Approval
GSK’s daprodustat, which is sold under the brand name Jesduvroq, has been granted class-first approval following two previous FDA rejections for oral anemia medications in the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) drug class. The drug is specifically approved for the treatment of chronic kidney disease patients with anemia who have been on dialysis for […]
Continue Reading